ACM
IPXL

Atika Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Atika Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-39,500
Closed -$499K – 95
2017
Q1 		$499K Buy
+39,500
New +$477K 0.24% 60

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Atika Capital Management's IPXL Position: Q2 2017 in Review

Atika Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2017, closing a stake of 39,500 shares — an estimated $499K sold.

Atika Capital Management first reported a position in IPXL in Q1 2017 and held it in 1 quarter. The position peaked at $499K in Q1 2017. 172 funds tracked by Wall St. Rank hold IPXL as of Q2 2017.

  • Atika Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2017 after selling out during the quarter.
  • Atika Capital Management sold 39,500 Impax Laboratories, Inc. shares in Q2 2017, an estimated $499K.
  • Atika Capital Management first reported a position in Impax Laboratories, Inc. in Q1 2017 and held it in 1 quarter.
  • Atika Capital Management's Impax Laboratories, Inc. position peaked at $499K in Q1 2017.
  • 172 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2017.

Based on Atika Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.